BlackRock Amends Agios Pharma Stake, Signals Passive Investment
Ticker: AGIO · Form: SC 13G/A · Filed: Jan 25, 2024 · CIK: 1439222
| Field | Detail |
|---|---|
| Company | Agios Pharmaceuticals, Inc. (AGIO) |
| Form Type | SC 13G/A |
| Filed Date | Jan 25, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock updated its passive stake in Agios Pharma as of year-end 2023.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 25, 2024, indicating its ownership of Common Stock in Agios Pharmaceuticals Inc. as of December 31, 2023. This amendment, number 6, updates previous disclosures about BlackRock's passive investment in the pharmaceutical company. This matters to investors because BlackRock is a major institutional investor, and changes in its holdings can signal its confidence (or lack thereof) in Agios Pharmaceuticals' future prospects.
Why It Matters
This filing shows BlackRock's updated, passive ownership in Agios Pharmaceuticals, which can influence market perception and investor confidence in the stock.
Risk Assessment
Risk Level: low — This is a routine update from a large institutional investor, indicating a passive stake, which typically carries low immediate risk.
Analyst Insight
Investors should note BlackRock's continued passive stake, but this filing alone doesn't suggest any immediate buy or sell action; it's a routine disclosure of institutional ownership.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Agios Pharmaceuticals Inc. (company) — the issuer of the securities
- December 31, 2023 (date) — the date of the event requiring the filing
- January 25, 2024 (date) — the filing date of the SC 13G/A
- 00847X104 (other) — the CUSIP number for Agios Pharmaceuticals Inc. Common Stock
Forward-Looking Statements
- BlackRock will maintain a passive investment strategy in Agios Pharmaceuticals Inc. for the foreseeable future. (BlackRock Inc.) — high confidence, target: December 31, 2024
FAQ
What type of filing is this and what does it generally indicate?
This is an SC 13G/A filing, which is an amendment to a Schedule 13G. It generally indicates that a passive institutional investor, like BlackRock Inc., has updated its ownership stake in a company, in this case, Agios Pharmaceuticals Inc.
Who is the reporting person in this filing?
The reporting person is BlackRock Inc., a major institutional investment manager, as stated in the 'FILED BY' section of the filing.
What is the subject company whose securities are being reported?
The subject company is AGIOS PHARMACEUTICALS, INC., identified by its CIK 0001439222 and its business address at 88 SIDNEY STREET, CAMBRIDGE, MA.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, as explicitly stated on the cover page of the Schedule 13G.
What rule under the Securities Exchange Act of 1934 is this Schedule 13G filed under?
This Schedule 13G is filed under Rule 13d-1(b), as indicated by the 'X' in the appropriate box on the cover page.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 25, 2024 regarding AGIOS PHARMACEUTICALS, INC. (AGIO).